Omri Yoffe

Omri Yoffe is the Founder and CEO of Vi Labs, an enterprise-AI platform for health that announced a $145 million transaction valuing the company at $1.64 billion in May 2026. Vi is designed to productize powerful data science models and deliver health and financial ROI across the entire value chain — from patient enrollment and engagement to operational efficiency. Vi already serves 100+ large scale enterprise customers, has helped bring 50+ drugs to market, supports over 190 million lives, and has generated more than $2 billion in measurable value across partners.

Yoffe is a former Israeli Air Force pilot and a graduate of the IAF Flight Academy with honors. He obtained his MBA from Northwestern University's Kellogg School of Management, which he attended from 2009 to 2011, and is a graduate of Singularity University at NASA Ames.

Career History

• Founder and CEO of Vi Labs (since July 2016), an enterprise AI platform that achieved $1.64 billion valuation in 2026
• Co-founder and CEO of LifeBEAM Technologies (2011–2016), an artificial-intelligence wearables technology company
• Founder and Chairman of Clear Cut Group (since 2009), an aerospace technology group focused on forward-thinking development methodologies and consumer tech utilization
• Founder of OFEK (2005), a non-profit organization that guides and empowers low socio-economical youth to become financially sustainable
• Israeli Air Force pilot (2000–2008)

Yoffe describes Vi as an "AI orchestrator" that integrates with healthcare systems to improve outcomes, drive innovation and ensure transparency. He emphasizes that Vi experts are focused on productizing and operationalizing AI that will actually drive health and financial outcomes for enterprises. Yoffe prioritizes AI transparency and explainability, advocating that these principles be embedded in AI models and products.

What Omri Yoffe could bring to his expanded role leading Vi: A track record of building and scaling multiple ventures from aerospace to wearable technology, combined with deep expertise in AI operationalization and health enterprise challenges. His military and aerospace background, paired with his focus on transparent, ROI-driven AI solutions, positions him to guide Vi's expansion into clinical trial acceleration and drug commercialization—markets demanding both technical rigor and ethical accountability. His demonstrated ability to create social impact alongside commercial success (through OFEK) suggests he can navigate the high-stakes ethics of deploying AI across healthcare's most critical functions while maintaining investor confidence in Vi's unicorn-stage growth trajectory.